American Society of Hematology

banner image

CME Credit & Certificate of Attendance

Obtain CME credit and a certificate of attendance for the 58th ASH Annual Meeting.

Learn more
banner image

2017 Highlights of ASH

Attend one of seven Highlights of ASH meetings featuring expert analysis of the 58th ASH Annual Meeting abstracts and sessions.

Learn more
banner image

Minority Medical Student Award Program

Applications are now available for the MMSAP, an 8-to-12 week research experience for students in their early years of medical school.

Learn more

Support Medical Research

Urge your members of Congress to support continued medical research funding.

Take action
Find a Hematologist

Find a Hematologist

Search a database of practicing hematologists in your area.

Learn more
Support Hematology

ASH Foundation

Help move hematology forward by supporting research, career development, and quality care and education programs.

Learn more
Join ASH

ASH Membership

Become part of a global network of more than 16,000 hematologists working to conquer blood diseases.

Learn more
  • 2017 ASH-AMFDP Scholars to Study Basic Insights in Blood Cancer Development

    The American Society of Hematology is pleased to announce that Justin Taylor, MD, of Memorial Sloan Kettering Cancer Center and Roger Belizaire, MD, PhD, of Brigham and Women’s Hospital have been selected to participate in the American Society of Hematology-Harold Amos Medical Faculty Development Program (ASH-AMFDP).

  • Kenneth C. Anderson, MD, Begins Term as 2017 ASH President

    Kenneth C. Anderson, MD, a world renowned expert in multiple myeloma, will serve as president of the American Society of Hematology for a year-long term through December 2017.

  • Studies Challenge Assumptions About Sickle Cell Trait and Cardiovascular Health

    Two new studies published in Blood address the need for improved understanding of sickle cell trait (SCT). These studies present valuable data on the cardiovascular health and fitness of individuals with SCT, suggesting that they face no greater risk of heart failure nor have diminished fitness compared to people without the trait.

  • Additions to Standard Multiple Myeloma Therapy Do Not Appear to Yield Additional Benefit

    Trial results being presented today during the 58th American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego suggest two therapies that are often added to standard therapy in patients with multiple myeloma do not improve rates of progression-free survival compared with the current standard course of treatment alone. The study is the largest randomized controlled trial of post-transplant therapy for multiple myeloma ever conducted in the United States.

View all press releases
View all policy news
View all Hematologist articles